CPHI to Hold Second Quarter 2018 Earnings Conference Call on Wednesday August 15, 2018 at 8:30 a.m. ET

HAIKOU, China, Aug. 6, 2018 /PRNewswire/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE MKT: CPHI), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that it plans to hold its second quarter 2018 earnings conference call on Wednesday, August 15, 2018 at 8:30 a.m. ET.Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 6869537.  A replay of the call will be accessible through August 23, 2018 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 6869537.About China Pharma Holdings, Inc.China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website.Contact:China Pharma Holdings, Inc. Ms. Diana Na Huang Phone: +86-898-6681-1730 (China) Email: hps@chinapharmaholdings.comView original content:http://www.prnewswire.com/news-releases/cphi-to-hold-second-quarter-2018-earnings-conference-call-on-wednesday-august-15-2018-at-830-am-et-300692284.htmlspan.prnews_span{font-size:8pt !important;font-family:"Arial" !important;color:black !important;} a.prnews_a{color:blue !important;} li.prnews_li{font-size:8pt !important;font-family:"Arial" !important;color:black !important;} p.prnews_p{font-size:0.62em !important;font-family:"Arial" !important;color:black !important;margin:0in !important;} ;}